Date: June 19th, 2025
IMMEDIATE PRESS RELEASE
CARDIO AI multi agents Collaborate for Advanced Cardiac Health Diagnosis and personalized treatment
“We’re thrilled to announce the completion of our multi-agentic system demo for for heart health”
A groundbreaking new project, the Heart Health Multi-Agent System Demo, is set to revolutionize cardiac health diagnosis and patient care through the innovative application of artificial intelligence agents working collaboratively. This demo project showcases the immense potential of AI to assist healthcare professionals in identifying and analyzing complex cardiac conditions with greater speed and accuracy.
About the Heart Health Multi-Agent System Demo:
The Heart Health Multi-Agent System Demo is a proof-of-concept project showcasing the potential of a collaborative network of AI agents to improve cardiac health diagnosis and patient care.
This demo utilizes a sophisticated network of specialized AI agents, each designed to focus on specific aspects of cardiac health. These agents can process and analyze diverse data sources, including simulated EHR, ECG, Echo, MRI and genetic data, to provide a comprehensive view of a patient's cardiac status. By working together, these agents can identify subtle patterns and correlations that might be missed by human eye, leading to earlier and more precise diagnoses of conditions such as heart attack, heart failure, arrhythmia, coronary artery disease, valve dysfunction (aortic stenosis, aortic regurgitation, mitral regurgitation), structural heart abnormalities and left ventricular hypertrophy (LVH).
"We believe that AI has the power to transform healthcare and not disrupt it, and our Heart Health Multi-Agent System Demo is a clear demonstration of that potential," said Sampson Kontomah, Founder & CEO of CARDIO AI. "By bringing together specialized AI agents in a collaborative framework, we can enhance the diagnostic process and ultimately contribute to better patient outcomes."
This project is not a finished product but a compelling demonstration of what is possible when cutting-edge AI is applied to the critical field of cardiac health. The development team is actively working towards launching this project shortly and is preparing for commercialization.
We’re currently seeking:
Investors: To secure funding to scale development and bring this powerful technology to market.
Early Adopters: Healthcare organizations and professionals interested in exploring the capabilities of this system in a real-world setting.
Beta Testers: Individuals and teams who can provide valuable feedback on the system's performance, usability, and accuracy.
The Heart Health Multi-Agent System Demo highlights the potential for:
Improved Diagnostic Accuracy: Our multi agentic system is targeted to analyze complex data and identify subtle indicators of cardiac issues.
Save Time to Diagnosis: Reducing the time it takes to process and interpret medical data for diagnostic and treatment
Enhanced Collaboration: Demonstrating how specialized AI agents can work together to provide a holistic view of patient health.
Potential for Personalized Medicine: Paving the way for more tailored treatment plans based on detailed multi-agentic-driven analysis.
The project's open and collaborative approach to showcasing this technology is a key aspect of its strategy for future development. The team is eager to partner with those who share their vision for advancing cardiac healthcare through AI.
For more information about CARDIO AI Heart Health Multi-Agent System Demo, to explore investment opportunities, or to inquire about becoming an early adopter or beta tester, please contact us through our website contact page at www.cardioailive.com or schedule a demo call at the following link.
https://calendly.com/tonywell-cardioailive/business-executives
Contact:
Sampson Kontomah
Founder & CEO
CARDIO AI
Email: [email protected]
Website: www.cardioailive.com
CARDIO AI POWERED CARDIOLOGY DEMO DISCLOSURE STATEMENT:
Marketing Disclosure Statement Product Name: Cardio AI-Powered Cardiology Solution Demo Development Status: The Cardio AI-Powered Cardiology Solution demo is currently in completion phase and has not been submitted for review or approval by the U.S. Food and Drug Administration (FDA) or any other regulatory bodies. Demo Purpose: This demonstration model is intended to showcase potential functionalities and applications of our innovative technology. It serves educational and informational purposes only and does not represent a final, market-ready product. The demo should not be used for clinical decision-making or as a substitute for professional medical advice, diagnosis, or treatment. Regulatory Compliance: We are committed to adhering to all applicable regulatory guidelines, including those set forth by the FDA, HIPAA, GDPR, and Good Clinical Practice (GCP): FDA Regulations: The demo does not imply FDA clearance or approval and should not be interpreted as such.
HIPAA Compliance: Any data presented in the demo is de-identified to protect patient privacy unless explicit consent has been obtained.
GDPR Compliance: We ensure that any personal data involved in the demo adheres to GDPR principles, including lawful processing and protection of data subject rights. Good Clinical Practice: The demo aligns with ethical standards and transparency as outlined in GCP guidelines.
Future Developments: As we continue to develop and refine the Cardio AI solution, updates will be provided regarding progress and forthcoming regulatory submissions. We appreciate your interest and support as we work towards bringing this promising technology to market.
Marketing Publications:
All marketing publications before and after this press release are subject to this “disclosure statement”
If you're interested in learning more about Cardio AI schedule a demo call using the following link.
https://calendly.com/tonywell-cardioailive/business-executives
Contact Information: CC: legal Attorney
Sampson Kontomah
Founder & CEO
CARDIO AI
www.cardioailive.com
This disclosure statement ensures clarity, transparency, and compliance, helping stakeholders understand the developmental nature of the product while maintaining adherence to regulatory requirements.
